All In Biotech

Drug Trial Radar · NCT07468071

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

25

Actual

Start

Jun 8, 2026

Primary completion

Jun 11, 2029

Study completion Sep 11, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.

Conditions

  • Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
  • Advanced Solid Tumors Harboring the KRAS G12C Mutation

Interventions

  • OpnurasibDrug

    Eligible participants will receive the same starting dose and regimen of opnurasib as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.

  • TNO155Drug

    Eligible participants will receive the same starting dose and regimen of any applicable combination drug as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.

  • trametinibDrug

    Eligible participants will receive the same starting dose and regimen of any applicable combination drug as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.

  • cetuximabBiological

    Eligible participants will receive the same starting dose and regimen of any applicable combination drug as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.

  • tislelizumabBiological

    Eligible participants will receive the same starting dose and regimen of any applicable combination drug as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants receiving opnurasib as single agent or in combination with other study treatmentsTime frame: Assessed up to approximately 3 years
  2. Duration of exposure to study treatmentTime frame: Assessed up to approximately 3 years

Locations

21 sites in 10 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Sint-Niklaas, Oost Vlaanderen, Belgium

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Sherbrooke, Quebec, Canada

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Bron, France

  • Novartis Investigative Site

    Saint-Herblain, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Kashiwa, Chiba, Japan

  • Novartis Investigative Site

    Koto Ku, Tokyo, Japan

  • Novartis Investigative Site

    Kuching, Sarawak, Malaysia

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Valencia, Spain

  • Novartis Investigative Site

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.